Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 400,000 shares at $26.10 ($10.4M) on 2020-06-16, disclosed to the SEC on 2020-06-18.
Open-market sale of $10.4M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |